首页> 美国卫生研究院文献>Journal of Clinical Microbiology >Results of Use of WHO Global Salm-Surv External Quality Assurance System for Antimicrobial Susceptibility Testing of Salmonella Isolates from 2000 to 2007
【2h】

Results of Use of WHO Global Salm-Surv External Quality Assurance System for Antimicrobial Susceptibility Testing of Salmonella Isolates from 2000 to 2007

机译:2000年至2007年使用WHO全球Salm-Surv外部质量保证系统对沙门氏菌分离株进行药敏试验的结果

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

An international External Quality Assurance System (EQAS) for antimicrobial susceptibility testing of Salmonella was initiated in 2000 by the World Health Organization (WHO) Global Salm-Surv in order to enhance the capacities of national reference laboratories to obtain reliable data for surveillance purposes worldwide. Seven EQAS iterations have been conducted from 2000 to 2007. In each iteration, participating laboratories submitted susceptibility results from 10 to 15 antimicrobial agents for eight Salmonella isolates and an Escherichia coli reference strain (ATCC 25922). A total of 287 laboratories in 102 countries participated in at least one EQAS iteration. A large number of laboratories reported results for the E. coli ATCC 25922 reference strain which were outside the quality control ranges. Critical deviations for susceptibility testing of the Salmonella isolates varied from 4% in 2000 to 3% in 2007. Consistent difficulties were observed in susceptibility testing of amoxicillin-clavulanic acid, cefotaxime, ceftazidime, streptomycin, sulfonamides, and tetracycline. Regional variations in performance were observed, with laboratories in central Asia, Africa, and the Middle East not performing as well as those in other regions. Results from the WHO Global Salm-Surv EQAS show that most laboratories worldwide are capable of correctly performing antimicrobial susceptibility testing of Salmonella isolates, but they also indicate that further improvement for some laboratories is needed. In particular, further training and dissemination of information on quality control, appropriate interpretive criteria (breakpoints), and harmonization of the methodology worldwide through WHO Global Salm-Surv and other programs will contribute to the generation of comparable and reliable antimicrobial susceptibility data (D. M. A. Lo Fo Wong, R. S. Hendriksen, D. J. Mevius, K. T. Veldman, and F. M. Aarestrup, Vet. Microbiol. 115:128-139, 2006).
机译:世界卫生组织(世卫组织)全球沙门氏菌检测于2000年启动了一个国际外部质量保证体系(EQAS),用于沙门氏菌的抗菌药敏试验,目的是增强国家参​​考实验室获取全球可靠监测数据的能力。从2000年到2007年,已经进行了7次EQAS迭代。在每次迭代中,参与实验室提交了8种沙门氏菌和一种大肠杆菌参考菌株(ATCC 25922)的10至15种抗菌剂的药敏结果。 102个国家/地区的287个实验室至少参与了一次EQAS迭代。大量实验室报告了大肠杆菌ATCC 25922参考菌株的结果,这些结果超出了质量控制范围。沙门氏菌分离物药敏试验的关键偏差从2000年的4%到2007年的3%不等。在阿莫西林-克拉维酸,头孢噻肟,头孢他啶,链霉素,磺酰胺和四环素的药敏试验中观察到一致的困难。观察到绩效存在地区差异,中亚,非洲和中东的实验室表现不如其他地区。世卫组织全球Salm-Surv EQAS的结果表明,全世界大多数实验室都能够正确进行沙门氏菌分离株的抗菌药敏试验,但它们也表明需要对某些实验室进行进一步改进。尤其是,通过WHO全球Salm-Surv和其他计划,进一步培训和传播有关质量控制,适当的解释标准(断点)以及全球方法学信息的协调,将有助于产生可比且可靠的抗菌药物敏感性数据(DMA Lo Fo Wong,RS Hendriksen,DJ Mevius,KT Veldman和FM Aarestrup,Vet。Microbiol。115:128-139,2006)。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号